Immunome (NASDAQ:IMNM) Stock Rating Reaffirmed by Wedbush

Immunome (NASDAQ:IMNM)‘s stock had its “outperform” rating reaffirmed by analysts at Wedbush in a report issued on Friday, Benzinga reports. They currently have a $33.00 price objective on the stock. Wedbush’s price objective would suggest a potential upside of 163.58% from the company’s previous close.

Separately, Piper Sandler reduced their price target on Immunome from $27.00 to $23.00 and set an “overweight” rating for the company in a research report on Tuesday, August 13th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $29.00.

Immunome Stock Performance

NASDAQ:IMNM traded up $0.51 during trading hours on Friday, reaching $12.52. The company’s stock had a trading volume of 103,123 shares, compared to its average volume of 768,328. Immunome has a 1 year low of $6.93 and a 1 year high of $30.96. The firm has a 50-day simple moving average of $13.96 and a 200-day simple moving average of $14.36. The firm has a market capitalization of $750.81 million, a price-to-earnings ratio of -1.66 and a beta of 1.76.

Immunome (NASDAQ:IMNM) last released its earnings results on Monday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). The business had revenue of $2.36 million during the quarter, compared to analysts’ expectations of $2.62 million. Immunome had a negative return on equity of 38.19% and a negative net margin of 2,435.02%. Equities analysts anticipate that Immunome will post -1.92 earnings per share for the current fiscal year.

Insider Activity at Immunome

In other news, CFO Max Rosett sold 14,380 shares of the business’s stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total transaction of $230,223.80. Following the transaction, the chief financial officer now owns 47,476 shares of the company’s stock, valued at approximately $760,090.76. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Immunome news, CFO Max Rosett sold 14,380 shares of the stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total value of $230,223.80. Following the sale, the chief financial officer now owns 47,476 shares in the company, valued at $760,090.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jean Jacques Bienaime acquired 7,000 shares of the stock in a transaction on Friday, August 16th. The stock was bought at an average cost of $13.94 per share, with a total value of $97,580.00. Following the completion of the transaction, the director now owns 16,615 shares in the company, valued at $231,613.10. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 8.60% of the stock is owned by insiders.

Institutional Trading of Immunome

Hedge funds have recently bought and sold shares of the stock. Capstone Investment Advisors LLC acquired a new position in Immunome during the 1st quarter valued at about $1,044,000. Swiss National Bank purchased a new stake in shares of Immunome during the 1st quarter worth about $1,762,000. Sei Investments Co. acquired a new stake in shares of Immunome during the 1st quarter valued at about $469,000. Lord Abbett & CO. LLC purchased a new position in shares of Immunome in the 1st quarter valued at about $10,994,000. Finally, Vanguard Group Inc. increased its stake in shares of Immunome by 16.1% in the 1st quarter. Vanguard Group Inc. now owns 2,019,738 shares of the company’s stock valued at $49,847,000 after purchasing an additional 279,712 shares in the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.